Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from bioAffinity Technologies, Inc. ( (BIAF) ) is now available.
On January 7, 2026, bioAffinity Technologies announced that its subsidiary Precision Pathology Laboratory Services in San Antonio successfully maintained its accreditation from the College of American Pathologists following a rigorous on-site inspection, reaffirming that the lab meets leading standards for quality, accuracy and patient safety. The CAP accreditation, viewed as the gold standard in laboratory quality, underpins the company’s CyPath® Lung test—designed to detect lung cancer as early as Stage 1A with clinical data showing 92% sensitivity and 87% specificity—and strengthens bioAffinity’s value proposition to physicians, health systems and partners as it seeks to grow revenue in a U.S. lung cancer diagnostics market estimated at $4.8 billion in 2024 and projected to more than double by 2034.
The most recent analyst rating on (BIAF) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.
Spark’s Take on BIAF Stock
According to Spark, TipRanks’ AI Analyst, BIAF is a Neutral.
The score is held down primarily by weak financial performance (declining revenue, large losses, negative operating cash flow and ROE) and a bearish technical setup (below major moving averages with negative MACD). Corporate events provide some offset via positive product/IP and compliance updates, while valuation is difficult to support with a negative P/E and no dividend yield data.
To see Spark’s full report on BIAF stock, click here.
More about bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. is a biotechnology company focused on noninvasive diagnostics and early detection of lung cancer and other lung diseases, as well as broad-spectrum cancer treatments. Its flagship product, CyPath® Lung, is a laboratory-developed, noninvasive diagnostic test marketed through its subsidiary Precision Pathology Laboratory Services, which also provides anatomic and clinical pathology, histological, morphological staining and molecular testing services to outpatient physicians in the U.S. lung cancer diagnostics market.
Average Trading Volume: 1,064,207
Technical Sentiment Signal: Sell
Current Market Cap: $5.62M
See more data about BIAF stock on TipRanks’ Stock Analysis page.